Hybrid LNP Prime Dendritic Cells for Nucleotide Delivery.
Adv Sci (Weinh)
; 10(33): e2303576, 2023 11.
Article
em En
| MEDLINE
| ID: mdl-37814359
ABSTRACT
The efficient activation of professional antigen-presenting cells-such as dendritic cells (DC)-in tumors and lymph nodes is critical for the design of next-generation cancer vaccines and may be able to provide anti-tumor effects by itself through immune stimulation. The challenge is to stimulate these cells without causing excessive toxicity. It is hypothesized that a multi-pronged combinatorial approach to DC stimulation would allow dose reductions of innate immune receptor-stimulating TLR3 agonists while enhancing drug efficacy. Here, a hybrid lipid nanoparticle (LNP) platform is developed and tested for double-stranded RNA (polyinosinicpolycytidylic acid for TLR3 agonism) and immune modulator (L-CANDI) delivery. This study shows that the ≈120 nm hybrid nanoparticles-in-nanoparticles effectively eradicate tumors by themselves and generate long-lasting, durable anti-tumor immunity in mouse models.
Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Vacinas Anticâncer
/
Neoplasias
Limite:
Animals
Idioma:
En
Revista:
Adv Sci (Weinh)
Ano de publicação:
2023
Tipo de documento:
Article